Yangambin is a selective antagonist of the cardiovascular effects of platelet activating factor (PAF); it has hypotensive effect, which is probably due to a peripheral vasodilatation that involves, at least, the inhibition the Ca2+ influx through voltage-gated Ca2+ channels. Yangambin has central nervous system activity, it presents a depressant activity in the open field, forced swimming and pentobarbital sleeping time tests.

Flosatidil is a small molecule voltage-gated calcium channel complex (VDCCs) blocker for the treatment of neurological disorders and cardiovascular diseases, and can be used in the study of angina pectoris.

ABT-639 is a novel, peripherally acting, selective T-type calcium channel blocker.